PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation session by principal investigator Paul D. Thompson, M.D., on November 18 at the 2013 Scientific Sessions of the American Heart Association in Dallas. Later in the day, the Company will webcast a briefing of the results.
The Phase 2 proof-of-concept study was designed to evaluate the LDL-C lowering efficacy, safety and tolerability of ETC-1002 compared with placebo in patients with hypercholesterolemia and a history of intolerance to two or more statins. In June 2013, Esperion previously announced positive topline results from this study, which demonstrated that ETC-1002 lowered LDL-C greater than 30 percent and was well tolerated.
Details of the oral presentation follow:
- Title: ETC-1002 Lowered LDL-C and Was Well Tolerated in Hypercholesterolemia Patients with Statin Intolerance
- Presenter: Paul D. Thompson, M.D., Director of Cardiology, Cardiovascular Research at Hartford Hospital, and Professor of Medicine at the University of Connecticut
- Date/Time: Monday, November 18, 2:30-2:45 p.m. Central Time
- Session: George L. Duff Memorial Lecture and Therapeutic Approaches for Treating Dyslipidemia
- Location: Room D167
Webcast Briefing Details
Esperion will host a briefing on Monday, November 18, from 7:00 to 9:00 p.m. Central Time separate from the AHA Scientific Sessions in Dallas. During the event, the Company will provide an update on its recent business progress, and the featured guest, Dr. Thompson, will provide a recap of the ETC-1002-006 full results. A live webcast of the event will be available via the Esperion website at www.esperion.com. A replay of the webcast will be available on the Company's website for 90 days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002, Esperion’s lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule therapy designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and has initiated a robust Phase 2b clinical program. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of ETC-1002. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on November 6, 2013. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.